-
First line immunotherapy for renal cell carcinoma and head and neck cancer! Kestruda has been approved three first-line treatment indications in Japan!
Time of Update: 2019-12-23
December 23, 2019 / BIOON / -- cancer immunotherapy giant Merck & Co recently announced that Japan's drugs and medical devices The PMDA has approved three new first-line treatment indications of keytr
-
New breast cancer drug! Kadcyla, a Roche targeted anticancer drug, was approved by the European Union to assist in the treatment of HER2 positive early breast cancer
Time of Update: 2019-12-20
December 20, 2019 / BIOON / - Roche, a Swiss pharmaceutical giant, recently announced that the European Commission (EC) has approved the HER2 targeted drug kadcyla (trastuzumab emtansine) for the trea
-
Immunotherapy for NMIBC! The new indications of kestruda have been recommended and approved by FDA Expert Committee!
Time of Update: 2019-12-19
December 19, 2019 / BIOON / -- cancer immunotherapy giant Merck & Co recently announced that the US Food and Drug Administration (FDA) cancer The Drug Advisory Committee (ODAC) voted 9-4 to approve ke
-
Pancreatic cancer is a big news! AstraZeneca / mesardon lynparza (Lipitor) in the treatment of gbrcam pancreatic cancer was supported by the US FDA expert committee!
Time of Update: 2019-12-19
December 19, 2019 / BIOON / -- AstraZeneca and its partner Merck & Co recently jointly announced that FDA cancer According to the results of 7-5 votes, the Drug Advisory Committee (ODAC) proposed to a
-
The first new drug of Globo h target! Taiwan Haoding antibody drug conjugate obi-999 launched the first human clinical research, treatment of a variety of solid tumors!
Time of Update: 2019-12-19
December 19, 2019 / bioun / -- Taiwan Haoding Biotechnology Co., Ltd (Obi Pharma, Inc., hereinafter referred to as Haoding) recently announced the launch of a phase I / II clinical study (nct04084366)
-
The first BCMA targeted therapy in the world! The key clinical success of GSK antibody drug conjugate gsk2857916 multiple myeloma is to apply for listing!
Time of Update: 2019-12-18
December 18, 2019 / Biovalley BIOON / -- British pharmaceutical giant GSK announced recently that the evaluation of B cell mature antigen (BCMA) targeted antibody drug conjugate (ADC) belantamab mafod
-
Immunotherapy for lung cancer! Mosadon keytruda combined with first-line chemotherapy significantly prolonged progression free survival, not related to KRAS mutation!
Time of Update: 2019-12-17
December 17, 2019 / BIOON / -- cancer immunotherapy giant Merck & Co recently released exploratory analysis data of key phase III keynote-189 (nct02578680) study of lung cancer The results showed that
-
Immunotherapy for lung cancer! Mosadon keytruda single drug first-line treatment significantly prolonged the overall survival, and KRAS mutation was not related!
Time of Update: 2019-12-16
December 16, 2019 / BIOON / -- cancer immunotherapy giant Merck & Co recently released exploratory analysis data of key phase III keynote-042 study of lung cancer The results showed that PD-L1 (tumor
-
Keytruda three negative breast cancer latest data positive Tecentriq failed
Time of Update: 2019-12-15
Currently, Roche's tecentriq is the only tumor immunotherapy approved for the treatment of triple negative breast cancer (TNBC) However, the latest clinical data of keysruda in refractory TNBC seems t
-
First line treatment in line with stem cell transplantation of the newly diagnosed multiple myeloma! The darzalex + VTD scheme of Johnson & Johnson has been recommended and approved by the European Union CHMP!
Time of Update: 2019-12-15
December 15, 2019 / BIOON / -- Janssen Pharmaceutical, a subsidiary of JNJ, recently announced that the European Drug Administration (EMA) human pharmaceutical products Committee (CHMP) has issued act
-
Melanoma "immune + targeted" treatment! The three drug regimen of Roche tecentriq was successful in the treatment of stage III of BRAF V600 positive advanced patients!
Time of Update: 2019-12-14
December 14, 2019 / BIOON / -- Roche recently announced the positive results of the phase III study of the melanoma The study, a double-blind, placebo-controlled study, was conducted in patients with
-
Domestic PD-1 antibody! Baiji Shenzhou tirelizumab combined with sitravatinib in the treatment of platinum resistant ovarian cancer shows therapeutic potential!
Time of Update: 2019-12-14
December 14, 2019 news / Biogen / -- biogene is a biomedical company in the commercial stage, focusing on the development and commercialization of innovative molecular targeting and tumor immune drugs
-
Amgen bite immunotherapy combined with Revlimid can prevent mm recurrence
Time of Update: 2019-12-14
At last year's annual meeting of the American Society of Hematology (ash), Amgen's anti BCMA T-cell binding agent achieved a response rate of 70% in early clinical trials for the treatment of multiple
-
Domestic PD-L1 antibody! Cornerstone pharmaceutical cs1001 showed strong efficacy in relapsed / refractory extranodal NK / T-cell lymphoma, with a complete remission rate of 33.3%
Time of Update: 2019-12-13
December 13, 2019 / BIOON / -- Cornerstone Pharmaceutical (Suzhou) Co., Ltd (hereinafter referred to as "cornerstone pharmaceutical") recently published the latest experimental data of cs1001-201 rese
-
Chinese scientists in the United States have made great achievements: reprogramming T cells to enhance cancer immune response
Time of Update: 2019-12-13
Chinese scientists at St Jude Children's research hospital in the United States have found a molecular "brake" that limits the effectiveness of adoptive cell therapy This new treatment strategy can en
-
China's non resectable stage III non-small cell lung cancer ushers in a new era of immunotherapy! Imfinzi, the AstraZeneca PD-L1 inhibitor, was approved!
Time of Update: 2019-12-13
December 13, 2019 / BIOON / -- AstraZeneca AstraZeneca recently announced that China's National Drug Administration (nmpa) has officially approved durvalumab, the PD-L1 immunosuppressant, for the trea
-
The first car-t cell therapy for mantle cell lymphoma (MCL) in the world! Gilead second cell therapy kte-x19 in the United States to apply for listing!
Time of Update: 2019-12-13
December 13, 2019 / BIOON / -- kit, a T-cell treatment company owned by Gilead, recently announced that it has submitted to the U.S Food and Drug Administration (FDA) a biological product licensing ap
-
T cell amplifier + immunotherapy! Nit cooperates with MSD to evaluate the efficacy of hyeukin-7 and keytruda in the treatment of relapsed / refractory advanced solid tumors!
Time of Update: 2019-12-13
December 13, 2019 / BIOON / -- neoimmunotech (NIT) is a clinical stage biopharmaceutical company focusing on the development of T-cell therapy Recently, the company announced that it has signed a clin
-
Multiple myeloma new program! Amgen / Johnson kyrolis + dexamethasone + darzalex (KDD) phase III clinical manifestation of deep lasting remission!
Time of Update: 2019-12-12
December 12, 2019 / BIOON / -- the 61st annual meeting of the American Society of Hematology (ash2019) was recently held in Orlando, Florida, USA At the meeting, Amgen announced the results of candor
-
BCMA car-t therapy made in China! Clinical data of Xinda biological / reindeer medical cooperative product ibi326 was presented at ash annual meeting, with a total remission rate of 100%!
Time of Update: 2019-12-12
December 12, 2019 news / BIOON / -- Xinda biopharmaceutical Co., Ltd is a biopharmaceutical company dedicated to R & D, production and sales of innovative drugs for the treatment of major diseases suc
